Selcia in sp2-Magazine: Developing Drugs Targeting Peptidyl-Prolyl Isomerases

Selcia has developed new technology to enable drug discovery and development on the target family of peptidyl-prolyl cis-trans isomerases (PPIases).

The company's business development director Simon Bury explains how this new launch fits into Selcia's strategy to apply innovative solutions to deliver high quality drug candidates to the global life science industry. To read the full article please navigate to the sp2 InterActive MarchApril 2013 issue via the following link. The article starts on page 16.